Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Retina > Breakthrough imaging and treatment advances define 2024’s retinal research
  • Retina

Breakthrough imaging and treatment advances define 2024’s retinal research

Kelsey Moroz

2024’s retinal research highlights breakthrough imaging techniques and treatment comparisons, enhancing diagnostic accuracy

 

Hidden retinal issues detected by OCT in patients with normal fundoscopic exams

A study found that optical coherence tomography detected retinal pathologies in 14% of patients recommended for cataract surgery, despite normal findings in traditional eye exams. Common issues included epiretinal membranes, age-related macular degeneration, and vitreomacular traction, with most affected patients over 70 years old.

Read more here.

 

Visual acuity outcomes similar for anti-VEGF and surgery in submacular hemorrhage

A study found that both anti-VEGF injections and surgical interventions are effective for treating submacular hemorrhage due to neovascular age-related macular degeneration, with similar visual acuity outcomes. However, anti-VEGF injections have a better safety profile, with fewer complications such as cataracts, proliferative vitreoretinopathy, and retinal detachment compared to surgery.

Read more here.

 

Dr. Nimesh Patel highlights advancements in diagnostics and treatments for retinal diseases

Nimesh Patel, MD, a retina specialist focusing in pediatric retina at the Mass Eye and Ear Infirmary in Boston Children’s Hospital and Assistant Professor of Ophthalmology at Harvard Medical School and the Director of Pediatric Retina, discusses the many advancements in both diagnostics and treatment in the retina realm.

Read more here.

 

Blurred vision most common cause of unscheduled follow-up after intravitreal injections

A study found that blurry vision was the most common reason for unscheduled follow-up visits within 7 days after an intravitreal injection, with 37.2% of patients seeking urgent care. Aflibercept, bevacizumab, and ranibizumab were the most frequently associated medications with these visits, and the average time to follow-up was 3.96 days.

Read more here

 

Peripheral retinal degenerations more easily identified with UWF SS-OCT

A study found that ultra-widefield swept source optical coherence tomography (UWF SS-OCT) significantly improves the diagnosis of peripheral retinal degenerations by providing detailed imaging that is often missed with routine ophthalmoscopy. The technology successfully imaged various retinal lesions, such as lattice degeneration and snail track lesions, revealing important structural details that enhance diagnostic accuracy and enable early detection of vision-threatening conditions.

Read more here.

Share

Related Content

  • Retina

Switching to aflibercept 8 mg improved anatomical outcomes in previously treated nAMD

Neovascular Age-related Macular Degeneration: Emerging Therapies With an EYE On Treatment Frequency
  • Retina

Treat-and-extend aflibercept 8 mg improves outcomes in nAMD over 1 year

  • Retina

Intravitreal therapy in nAMD linked to lower depression and anxiety risk

  • Retina

Alternative aflibercept regimens maintained efficacy in wet AMD

  • Retina

Nanoscope Therapeutics is working on the potential first-ever optogenetic therapy for retinal diseases

  • Retina

Real-world study finds similar efficacy between faricimab and aflibercept in DMO

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon